Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Leiden, the Netherlands, November 5, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST® and Joenja® revenue growthRUCONEST® third quarter...
Pharming Group reports third quarter 2024 financial results and provides business update Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023...
Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2024...
Pharming Group to report third quarter 2024 financial results on October 24 Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR...
Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to include ALPS-FAS, CTLA4 haploinsufficiency...
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation Proof of concept clinical trial will evaluate leniolisib in...
For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands...
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib) For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated...
Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.028 | -3.91061452514 | 0.716 | 0.7395 | 0.687 | 3214841 | 0.71600483 | DE |
| 4 | -0.112 | -14 | 0.8 | 0.825 | 0.687 | 5285241 | 0.75771568 | DE |
| 12 | -0.016 | -2.27272727273 | 0.704 | 0.862 | 0.654 | 4914339 | 0.74977617 | DE |
| 26 | -0.145 | -17.4069627851 | 0.833 | 0.862 | 0.6475 | 4221508 | 0.75914984 | DE |
| 52 | -0.406 | -37.1115173675 | 1.094 | 1.22 | 0.6475 | 5250527 | 0.92085042 | DE |
| 156 | -0.082 | -10.6493506494 | 0.77 | 1.419 | 0.6475 | 5877003 | 1.01738463 | DE |
| 260 | -0.512 | -42.6666666667 | 1.2 | 1.64 | 0.6475 | 6938721 | 1.08616375 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
2
